July 16, 2025, Ningbo – Tianxuan Medical Testing Laboratory in Jiangbei, Ningbo, a wholly-owned subsidiary of Zhejiang Tianyuan Biotechnology Co., Ltd., has secured first place in the Entrepreneurship category at the Jiangbei Preliminary Round of the 10th "Maker China" Ningbo SME Innovation and Entrepreneurship Competition. Centered on the theme "Showcasing Innovation and Entrepreneurship, Winning the Future by Chasing Dreams in Yong City", the competition focused on nurturing high-quality SMEs, aiming to discover and cultivate outstanding maker teams and tech enterprises to advance new industrialization in Jiangbei District.

      At the event, Mr. Jiao Mingming, General Manager of Tianyuan Biotechnology, delivered a roadshow presentation titled "The DeepSeek Era of Biotechnology: iPS Cells Offer Hope for Myocardial Repair and Regeneration". He detailed the cutting-edge applications of iPS cell technology (induced pluripotent stem cells) in cardiac muscle repair and regeneration. As a groundbreaking biotechnology, iPSCs can differentiate into various human cell types, opening new pathways for treating cardiovascular diseases such as heart failure.

      During the Q&A session, Dr. Chen Junjie, Technical Director of Tianyuan Biotechnology—a Ph.D. graduate from the University of Oxford and postdoctoral fellow at Harvard Medical School—joined the stage. Leveraging his deep expertise and practical experience, Dr. Chen provided thorough and precise responses to judges' inquiries. His contributions highlighted the company’s technical leadership in iPSC research, particularly its domestic-leading pacemaker-like organoids, proprietary differentiation and testing methods, and the use of 3D culture technology to develop biological pacemakers that address the limitations of traditional metal pacemakers.

      Backed by Tianyuan Biotechnology’s technological expertise in cell therapy, Tianxuan Medical Testing Laboratory is committed to advancing iPSC technology into clinical applications and driving deeper integration between biotechnology and healthcare. Winning first place not only recognizes the lab’s achievements in iPSC-based myocardial repair and regeneration but also affirms Tianyuan’s innovative efforts in biotechnology.

      Moving forward, Tianyuan Biotechnology will continue to increase R&D investment, deepen technological innovation, and expand application scenarios to further contribute to the growth of the biotechnology industry. The company will actively participate in innovation initiatives and strengthen collaboration across the sector to jointly advance the integration of biotechnology and healthcare, creating greater value for human health.